Poland
· Delayed Price · Currency is PLN Read-Gene Statistics
Total Valuation
Read-Gene has a market cap or net worth of PLN 50.58 million. The enterprise value is 52.97 million.
| Market Cap | 50.58M |
| Enterprise Value | 52.97M |
Important Dates
The next estimated earnings date is Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Read-Gene has 11.79 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 11.79M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.16% |
| Owned by Institutions (%) | n/a |
| Float | 1.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.94 |
| PB Ratio | 15.97 |
| P/TBV Ratio | 15.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -53.18 |
| EV / Sales | 4.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.18, with a Debt / Equity ratio of 2.50.
| Current Ratio | 5.18 |
| Quick Ratio | 5.11 |
| Debt / Equity | 2.50 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.46 |
Financial Efficiency
Return on equity (ROE) is -27.17% and return on invested capital (ROIC) is -4.46%.
| Return on Equity (ROE) | -27.17% |
| Return on Assets (ROA) | -3.40% |
| Return on Invested Capital (ROIC) | -4.46% |
| Return on Capital Employed (ROCE) | -6.18% |
| Revenue Per Employee | 584,077 |
| Profits Per Employee | -45,273 |
| Employee Count | 22 |
| Asset Turnover | 0.86 |
| Inventory Turnover | 6.95 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.73% in the last 52 weeks. The beta is -0.99, so Read-Gene's price volatility has been lower than the market average.
| Beta (5Y) | -0.99 |
| 52-Week Price Change | -18.73% |
| 50-Day Moving Average | 4.46 |
| 200-Day Moving Average | 5.05 |
| Relative Strength Index (RSI) | 41.91 |
| Average Volume (20 Days) | 1,329 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Read-Gene had revenue of PLN 12.85 million and -995,997 in losses. Loss per share was -0.08.
| Revenue | 12.85M |
| Gross Profit | 11.98M |
| Operating Income | -811,924 |
| Pretax Income | -995,997 |
| Net Income | -995,997 |
| EBITDA | -332,184 |
| EBIT | -811,924 |
| Loss Per Share | -0.08 |
Balance Sheet
The company has 5.52 million in cash and 7.91 million in debt, giving a net cash position of -2.39 million or -0.20 per share.
| Cash & Cash Equivalents | 5.52M |
| Total Debt | 7.91M |
| Net Cash | -2.39M |
| Net Cash Per Share | -0.20 |
| Equity (Book Value) | 3.17M |
| Book Value Per Share | 0.27 |
| Working Capital | 6.77M |
Cash Flow
| Operating Cash Flow | 200,864 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 93.23%, with operating and profit margins of -6.32% and -7.75%.
| Gross Margin | 93.23% |
| Operating Margin | -6.32% |
| Pretax Margin | -7.75% |
| Profit Margin | -7.75% |
| EBITDA Margin | -2.59% |
| EBIT Margin | -6.32% |
| FCF Margin | n/a |
Dividends & Yields
Read-Gene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -1.97% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Read-Gene has an Altman Z-Score of 4.18.
| Altman Z-Score | 4.18 |
| Piotroski F-Score | n/a |